We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Looks Into Data Manipulation, Poor Record-keeping at Novartis Subsidiary
FDA Looks Into Data Manipulation, Poor Record-keeping at Novartis Subsidiary
The FDA is investigating a Novartis subsidiary over “data manipulation” reported only after the agency approved its gene therapy Zolgensma (onasemnogene abeparvovec-xioi).